Shanghai Pharmaceuticals Holding (601607.SH): Thiamphenicol sulfate injection passes generic drug consistency evaluation.

15:52 08/04/2026

Shanghai Pharmaceutical (601607.SH) announced recently that its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Shangyao Hefeng") received the "Drug Supplement Application Approval Notice" (Notice No.: 2026B01918) issued by the National Medical Products Administration for its Tobramycin Sulfate Injection. The drug has passed the evaluation for generic consistency.

Shanghai Pharmaceuticals Holding (601607.SH) announced that recently, its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Shanghai Pharmaceutical Hefeng") received the "Drug Supplementary Application Approval Notice" (Notice No.: 2026B01918) issued by the National Medical Products Administration. the drug passed the generic drug consistency evaluation. Sulfobutide sulfate injection is used for sepsis, septicemia, central nervous system infections (including meningitis), complicated and recurrent urinary tract infections, lung infections, abdominal infections (including peritonitis), bone infections, burns, skin and soft tissue infections caused by Pseudomonas aeruginosa, Proteus, Escherichia coli, Klebsiella, Enterobacter, or Acinetobacter species, or in combination with other antibiotics for severe staphylococcal infections (if resistant to methicillin).

YUEXIU PROPERTY (00123): Junying awarded a HK$1 billion regular loan financing.

On April 8th, MILLIONHOPE IND(01897) bought back 47,000 shares at a cost of HKD 216,100.

In the first three months, TIMES CHINA (01233) registered a total contract sales amount of approximately 882 million yuan, a decrease of 29.44% compared to the previous year.

YUEXIU PROPERTY (00123): Junying awarded a HK$1 billion regular loan financing.

On April 8th, MILLIONHOPE IND(01897) bought back 47,000 shares at a cost of HKD 216,100.

In the first three months, TIMES CHINA (01233) registered a total contract sales amount of approximately 882 million yuan, a decrease of 29.44% compared to the previous year.